Daniel Freeman, MD
Neurology · Jackson, MINPI 1336107374
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 861 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,916 and has fallen 85.4% since, to $425 in 2024.
Across 861 payments — averaging $14.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- EMD Serono, Inc.$1K
- Supernus Pharmaceuticals, Inc.$1K
- Amgen$1K
- Biogen$990
- UCB, Inc.$869
- plus $5K from 30 others
What the payments were for
- Food & beverage$12,03498%
- Education$2052%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 97 | $1,809 |
| EMD Serono, Inc. | 145 | $1,343 |
| Supernus Pharmaceuticals, Inc. | 129 | $1,338 |
| Amgen | 79 | $1,042 |
| Biogen | 59 | $990 |
| UCB, Inc. | 54 | $869 |
| Novartis | 50 | $806 |
| AbbVie(2 entities) | 48 | $778 |
| Lilly USA, LLC | 22 | $418 |
| Neurocrine Biosciences, Inc. | 17 | $277 |
| Sanofi | 17 | $275 |
| SK Life Science, Inc. | 18 | $241 |
| Eisai Inc. | 14 | $239 |
| Johnson & Johnson | 10 | $222 |
| Bristol Myers Squibb | 24 | $203 |
| Lundbeck LLC | 11 | $198 |
| Argenx US, Inc. | 7 | $146 |
| Upsher-smith Laboratories LLC | 4 | $130 |
| Biohaven Pharmaceuticals, Inc. | 9 | $112 |
| Pfizer | 6 | $109 |
| Arbor Pharmaceuticals, Inc. | 5 | $95 |
| Neurelis, Inc. | 4 | $81 |
| Genentech USA, Inc. | 6 | $78 |
| AstraZeneca | 4 | $76 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $66 |
| Adamas Pharmaceuticals, Inc. | 4 | $64 |
| E.r. Squibb & Sons, L.L.C. | 4 | $63 |
| Catalyst Pharmaceuticals, Inc. | 2 | $41 |
| Livanova USA, Inc. | 1 | $19 |
| Banner Life Sciences, LLC | 1 | $19 |
| Greenwich Biosciences, Inc. | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Vanda Pharmaceuticals Inc. | 1 | $13 |
| Tanabe Pharma America, Inc. | 1 | $11 |
How this compares
$12,239 in reported general payments places this provider in the 80th percentile of 652 neurology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 11 | $71,565 |
| Keppra XrLevetiracetam | 23 | $40,168 |
| Aimovig AutoinjectorErenumab-Aooe | 13 | $9,035 |
| Carbamazepine ErCarbamazepine | 48 | $6,243 |
| Lacosamide | 33 | $2,624 |
| Levetiracetam | 73 | $2,516 |
| Levetiracetam ErLevetiracetam | 24 | $2,191 |
| Divalproex Sodium ErDivalproex Sodium | 30 | $1,854 |
| Lamotrigine | 93 | $1,614 |
| Propranolol Hcl ErPropranolol Hcl | 15 | $1,420 |
| Clobazam | 15 | $1,335 |
| Primidone | 21 | $1,308 |
| Pregabalin | 16 | $1,280 |
| Divalproex Sodium | 11 | $898 |
| Topiramate | 56 | $807 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $277 | $71,56511 claims |
| Upsher-smith Laboratories LLCTopiramate | $130 | $80756 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 652 neurology providers in Michigan.
Other neurology in Jackson
- John WaldJackson$434K
- Aaron EllenbogenFarmington Hills$1.6M
- Matthew HoltzmanWayne$1.4M
- Richard TroschFarmington Hills$1.2M
- Wade CooperAnn Arbor$991K
- Bisena BulicaDetroit$900K
- Julie BurnhamMount Clemens$836K
- Amit MasihOkemos$785K
- Martin BelkinFarmington Hills$712K
- Robert PaceOwosso$693K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.